Trevi Therapeutics (TRVI) Shares Outstanding (2018 - 2026)

Trevi Therapeutics' Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $128.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 28.55% year-over-year to $128.4 million; the TTM figure through Mar 2026 stood at $128.4 million (up 28.55% YoY), while the FY2025 annual figure was $128.3 million, up 37.08% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $128.4 million, roughly flat from $128.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $128.4 million in Q1 2026, with the low at $30.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $99.3 million (2023), against an average of $94.5 million.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) jumped 220.1% in 2023, then dropped 5.48% in 2024.
• Trevi Therapeutics' Shares Outstanding (Entity) stood at $59.9 million in 2022, then surged by 65.21% to $99.0 million in 2023, then slipped by 5.48% to $93.6 million in 2024, then surged by 37.08% to $128.3 million in 2025, then rose by 0.08% to $128.4 million in 2026.
• Business Quant data shows TRVI's Shares Outstanding (Entity) at $128.4 million in Q1 2026, $128.3 million in Q4 2025, and $128.2 million in Q3 2025.